^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

Published date:
05/17/2004
Excerpt:
Our results suggest that cyclin D1 overexpression predicts for tamoxifen treatment resistance in breast cancer…
DOI:
10.1038/sj.bjc.6601831